These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8838434)
1. On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutamatergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia. Saletu B; Grünberger J; Anderer P; Linzmayer L; König P Br J Clin Pharmacol; 1996 Feb; 41(2):89-99. PubMed ID: 8838434 [TBL] [Abstract][Full Text] [Related]
2. Acute central effects of the calcium channel blocker and antiglutamatergic drug caroverine. Double-blind, placebo-controlled, EEG mapping and psychometric studies after intravenous and oral administration. Saletu B; Grünberger J; Anderer P; Linzmayer L; König P Arzneimittelforschung; 1995 Mar; 45(3):217-29. PubMed ID: 7741773 [TBL] [Abstract][Full Text] [Related]
3. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: II. Double-blind, placebo-controlled EEG mapping and psychometric studies under hypoxia. Saletu B; Grünberger J; Anderer P; Linzmayer L Methods Find Exp Clin Pharmacol; 1996; 18(1):67-81. PubMed ID: 8721258 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Saletu B; Hitzenberger G; Grünberger J; Anderer P; Zyhlarz G; Linzmayer L; Rameis H Int J Clin Pharmacol Ther; 1995 May; 33(5):249-62. PubMed ID: 7655763 [TBL] [Abstract][Full Text] [Related]
5. On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Saletu B; Grünberger J; Anderer R Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):510-24. PubMed ID: 2086492 [TBL] [Abstract][Full Text] [Related]
6. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry. Saletu B; Grünberger J; Linzmayer L; Anderer P Psychopharmacology (Berl); 1992; 109(1-2):30-40. PubMed ID: 1365669 [TBL] [Abstract][Full Text] [Related]
7. Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. Saletu B; Grünberger J; Linzmayer L; Anderer P J Neural Transm Park Dis Dement Sect; 1990; 2(4):305-25. PubMed ID: 2127674 [TBL] [Abstract][Full Text] [Related]
8. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies. Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889 [TBL] [Abstract][Full Text] [Related]
9. Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard and Hydergine) by EEG mapping and psychometry under hypoxia. Saletu B; Grünberger J; Anderer P; Linzmayer L; Pakesch G; Zyhlarz G Arch Gerontol Geriatr; 1994; 18(2):81-99. PubMed ID: 15374302 [TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102 [TBL] [Abstract][Full Text] [Related]
11. The hypoxia model in human psychopharmacology: neurophysiological and psychometric studies with aniracetam i.v. Saletu B; Grünberger J Hum Neurobiol; 1984; 3(3):171-81. PubMed ID: 6434496 [TBL] [Abstract][Full Text] [Related]
12. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia. Saletu B; Grünberger J; Anderer P; Linzmayer L Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257 [TBL] [Abstract][Full Text] [Related]
13. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies. Saletu B; Grünberger J; Linzmayer L Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):51-65. PubMed ID: 2921096 [TBL] [Abstract][Full Text] [Related]
14. Infusional high-dose application of the calcium-channel-blocking and antiglutamatergic agent caroverine in the treatment of alcohol withdrawal (DSM-III-R 291.80). Geretsegger C; Fartacek R Eur Neuropsychopharmacol; 1998 Aug; 8(3):191-4. PubMed ID: 9716312 [TBL] [Abstract][Full Text] [Related]
15. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L; Anderer P Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):12-27. PubMed ID: 2883677 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L Int Clin Psychopharmacol; 1986 Apr; 1(2):145-64. PubMed ID: 2883214 [TBL] [Abstract][Full Text] [Related]
17. Early clinical pharmacological trials with a novel partial benzodiazepine agonist/antagonist Ro 17-1812 using pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L Methods Find Exp Clin Pharmacol; 1986 Jun; 8(6):373-89. PubMed ID: 3736281 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Saletu B; Grünberger J; Anderer P; Linzmayer L; Semlitsch HV; Magni G Br J Clin Pharmacol; 1992 Jun; 33(6):589-601. PubMed ID: 1389931 [TBL] [Abstract][Full Text] [Related]
19. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative Actovegin: double-blind, placebo-controlled trials. Saletu B; Grünberger J; Linzmayer L; Anderer P; Semlitsch HV Neuropsychobiology; 1990-1991; 24(3):135-48. PubMed ID: 2135068 [TBL] [Abstract][Full Text] [Related]
20. Classification and determination of pharmacodynamics of a new antihypoxidotic drug, vinconate, by pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L; Wittek R Arch Gerontol Geriatr; 1984 Jul; 3(2):127-46. PubMed ID: 6476974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]